HIV and AIDS
Aquamid Reconstruction have through accumulating research been shown to accommodate all of the above demands of quality, safety and durability. The unique physicochemical properties of Aquamid
1. Carr A, HIV protease inhibitor-related lipodystrophy syndrome, Clin Inf Diseases, 2000;30(Suppl. 2):135–42.
2. Blanch J, Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1, Clin Inf Diseases, 2004;38:1464–70.
3. Lichtenstein KA, Clinical assessment of HIV-associated lipodystrophy in an ambulatory population, AIDS, 2001;15:1389–98.
4. McComsey GA, Improvement in lipoatrophy associated with HAART in HIV-infected patients switched from Stavudine to abacavir or zidovudine: the results from the TARHEEL study, Clin Inf Diseases, 2004;38:263–70.
5. Orlando G, Guaraldi G, De FD, et al., Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational, nonrandomized study, AIDS Patient Care STDS, 2007;21(11):833–42.
6. Guaraldi G, Fontdevila J, Christensen LH, et al., Surgical correction of HIV-associated facial lipoatrophy, AIDS, 2011;25(1):1–12.
7. Coleman SR, Facial recontouring with lipostructure, Clin Plast Surg, 1997;24(2):347–67.
8. Guaraldi G, Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation, Clin Inf Diseases, 2005;40(2):e13–5.
9. Gooderham M, Solish N, Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy, Dermatol Surg, 2005;31(1):104–8.
10. Barlow RE, Torres WE, Sones PJ Jr, Someren A, Sonographic demonstration of migrating silicone, AJR Am J Roentgenol,
1980;135(1):170–1.
11. Valantin MA, Ubron-Olivier C, Ghosn J, et al., Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA, AIDS, 2003;17(17):2471–7.
12. Christensen L, Breiting V, Janssen M, et al., Adverse reactions to injectable soft tissue permanent fillers, Aesthetic Plast Surg, 2005;29(1):34–48.
13. Narins RS, Jewell M, Rubin M, et al., Clinical conference: management of rare events following dermal fillers – focal necrosis and angry red bumps, Dermatol Surg, 2006;32(3):426–34.
14. Christensen LH, Nielsen JB, Mouritsen L, et al., Tissue integration of polyacrylamide hydrogel: an experimental study of periurethral, perivesical, and mammary gland tissue in the pig, Dermatol Surg, 2008;34(Suppl. 1):S68–77.
15. Karim RB, Hage JJ, van RL, et al., Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases, J Plast Reconstr Aesthet Surg, 2006;59(12):1409–14.
16. Bjarnsholt T, Tolker-Nielsen T, Givskov M, et al., Detection of bacteria by fluorescence in situ hybridization in culture-negative soft tissue filler lesions, Dermatol Surg, 2009;35(Suppl. 2):1620–4.
17. Christensen L, Breiting V, Vuust J, Hogdall E, Adverse reactions following injection wiht a permanent facial filler polyacrylamide hydrogel (Aquamid): causes and treatment, Eur J Plast Surg, 2005;28:464–71.
18. Negredo E, Higueras C, Adell X, et al., Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a
and Aquamid Reconstruction result in a fully biocompatible and integrated implant that will remain soft and natural with no need of additional injections. n
prospective study comparing autologous fat and synthetic substances, AIDS Patient Care STDS, 2006;20(12):829–37.
19. Guaraldi G, Orlando G, De FD, et al., Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study, Antivir Ther, 2005;10(6):753–9.
20. Christensen L, Breiting V, Aasted A, et al., Long term effects of polyacrylamide hydrogel in human breast tissue, Plast Reconstr Surg, 2003;111:1830–90.
21. von Buelow S, Pallua N, Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation in a 2-year follow-up: a prospective multicenter study for evaluation of safety and aesthetic results in 101 patients, Plast Reconstr Surg, 2006;118(3 Suppl.):85S–91S.
22. Negredo E, Puig J, Aldea D, et al., Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy, AIDS Res Hum Retrovir, 2009;25(4):451–5.
23. Mansor S, Breiting VB, Dahlstrom K, et al., Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients, Aesthetic Plast Surg, 2011;(Epub ahead of print).
24. Pallua N, Wolter TP, A 5-year assessment of safety and aesthetic results after facial soft-tissue augmentation with polyacrylamide hydrogel (Aquamid): a prospective multicenter study of 251 patients, Plast Reconstr Surg, 2010;125(6):1797–804.
25. De SG, Jacob V, Baccarani A, et al., Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: a 2-year clinical experience, Plast Reconstr Surg, 2008;121(2):644–53.
82
EUROPEAN INFECTIOUS DISEASE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92